Profil de l'entreprise

Vous venez de lire:

Landmark Phase III Study of Bayer's Xarelto® (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery Disease

Nouvelles fournies par

Bayer HealthCare

Nov 13, 2012, 08:57 ET